Evidence map›Paper›PMID 27377706›Full record

SynthesisThe journal of headache and pain2016

Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials.

Mostafa Ebraheem Morra, Ahmed Elgebaly, Ahmed Elmaraezy, Adham M Khalil, Ahmed M A Altibi, Tran Le-Huy Vu, Mostafa Reda Mostafa, Nguyen Tien Huy, Kenji Hirayama

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The journal of headache and pain, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06216886 (Randomized Controlled Trial of Intradermal Injections of OnabotulinumtoxinA vs Saline for Trigeminal Neuralgia.), which is not on this map. Cited by 47 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 8 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06216886 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

Randomized Controlled Trial of Intradermal Injections of OnabotulinumtoxinA vs Saline for Trigeminal Neuralgia.

TypeinterventionalSponsorStanford UniversityRan2024 to 2027Enrolled20ConditionsTrigeminal NeuralgiaArmsOnabotulinumtoxinA 100 UNT [Botox], Sodium Chloride 0.9% for Injection, Preservative Free
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 8 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Observational
  15. Article
  16. Review
  17. Pathophysiology and Management of Refractory Trigeminal Neuralgia.Current neurology and neuroscience reports · 2024
    Review
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 5 countries.

Mostafa Ebraheem MorraFaculty of Medicine, Al Azhar University, Cairo, 11884, Egypt.
Ahmed ElgebalyFaculty of Medicine, Al Azhar University, Cairo, 11884, Egypt.
Ahmed ElmaraezyFaculty of Medicine, Al Azhar University, Cairo, 11884, Egypt.
Adham M KhalilFaculty of Medicine, Zagazig University, Zagazig, 44519, Egypt.
Ahmed M A AltibiFaculty of Medicine, University of Jordan, Amman, 11942, Jordan.
Tran Le-Huy VuUniversity of California, Los Angeles, Los Angeles, CA, 90095, USA.
Mostafa Reda MostafaFaculty of Medicine, Tanta University, Tanta, 31527, Egypt.
Nguyen Tien HuyDepartment of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program, and Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan. tienhuy@nagasaki-u.ac.jp.ORCID http://orcid.org/0000-0002-9543-9440
Kenji HirayamaDepartment of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program, and Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan. hiraken@nagasaki-u.ac.jp.
Al-Azhar University · EGNagasaki University · JPTanta University · EGUniversity of California, Los Angeles · USUniversity of Jordan · JOUniversity of Medicine and Pharmacy at Ho Chi Minh City · VNZagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral different interventions have been examined to alleviate pain and reduce frequency of trigeminal neuralgia (TN) paroxysms. However, some patients continue to have persistent or recurrent painful attacks. Using a systematic review and meta-analysis approach, we aimed to synthesize evidence from published randomized controlled trials (RCTs) regarding safety and efficacy of botulinum toxin type A (BTX-A) as a possible emerging choice of treatment for TN.

methodsWe conducted an electronic search in 10 databases/electronic search engines to access relevant publications. All articles in all languages reporting RCTs on the efficacy and safety of BTX-A in the treatment of TN were included for systematic review and meta-analysis.

resultsA total of four RCTs (n = 178) were identified for final meta-analysis. The overall effect favored BTX-A versus placebo in terms of proportion of responders (risk ratio RR = 2.87, 95 % confidence interval CI [1.76, 4.69], p <0.0001) with no significant detected heterogeneity (p = 0.31; I(2) = 4 %). Paroxysms frequency per day was significantly lower for BTX-A group (mean difference MD = -29.79, 95 % CI [-38.50,-21.08], p <0.00001) with no significant heterogeneity (p = 0.21; I(2) = 36 %).

conclusionDespite limited data, our results suggest that BTX-A may be an effective and safe treatment option for patients with TN. Further larger and well-designed RCTs are encouraged to translate these findings into better clinical outcome and better quality of life for TN patients.

Indexed as

Botulinum Toxins, Type ADatabases, FactualEdemaHematomaHumansPain MeasurementQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeTrigeminal NeuralgiaBotulinum Toxins, Type ABotulinumBTX-AClinical trialsMeta-analysisSystematic reviewTrigeminal neuralgia

Identifiers

PMID27377706
PMCPMC4932020
OpenAlexW2467606791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.